Russian biopharmaceutical company Nanolek and China’s Suzhou Alphamab have signed a strategic agreement to bring the drug armocibat to the Eurasian region for bleeding prophylaxis in haemophilia A and B. The document was signed during the Russia-China Pharmaceutical Forum in Shanghai. Nanolek views the collaboration as part of expanding its orphan drug portfolio, the Russian manufacturer’s press service told GxP News.
Under the agreement, Nanolek will receive exclusive rights for registration, promotion and distribution of the drug in Russia, the EAEU countries, Azerbaijan and Uzbekistan, and will hold the marketing authorisations. Armocibat is administered subcutaneously, which is more convenient than intravenous injections, and is intended for patients with both inhibitor‑positive and inhibitor-negative haemophilia. The drug is currently undergoing Phase III clinical trials in China, with completion expected in mid‑2027.
According to the registry, more than 8,500 patients in Russia have haemophilia A and B. In the inhibitor form, where the body produces antibodies to clotting factors, standard therapy becomes ineffective. The arrival of a TFPI inhibitor in Russian practice will be the first drug in its class for bleeding prophylaxis regardless of the presence of inhibitors.
Nanolek was founded in 2011, is listed among systemically important enterprises and manufactures vaccines and orphan drugs. The company’s portfolio includes paediatric vaccines, including Russia’s first HPV vaccine registered in March 2025, as well as oncology, haematology and orphan medicines. The company has more than 800 employees.
Earlier Nanolek was reported to have built one of the largest biopharmaceutical manufacturing complexes in the Kirov region, where it carries out technology transfer, localisation and industrial production of drugs in line with international GMP standards.
